Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator - Concepedia

Concepedia

Publication | Open Access

Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

DOI Full Paper Access

60

Citations

44

References

2004

Year

Carol J. Fabian, Bruce F. Kimler, Julie Anderson, Ossama Tawfik, Matthew S. Mayo, William E. Burak, Joyce O’Shaughnessy, Kathy S. Albain, David M. Hyams, G. Thomas Budd,

Clinical Cancer Research

Abstract

Given the favorable side effect profile and the biomarker modulations reported here, arzoxifene remains a reasonable candidate for additional study as a breast cancer chemoprevention agent.

References

	Year	Citations

Page 1